Investigational Drug Information for Etrumadenant

What is the development status for investigational drug Etrumadenant?

Etrumadenant is an investigational drug.

There have been 20 clinical trials for Etrumadenant. The most recent clinical trial was a Phase 1 trial, which was initiated on May 10^th 2024.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Arcus Biosciences, Inc., Gilead Sciences, and Infinity Pharmaceuticals, Inc.

There are sixty-two US patents protecting this investigational drug and twenty-four international patents.

Summary for Etrumadenant

US Patents	62
International Patents	24
US Patent Applications	208
WIPO Patent Applications	161
Japanese Patent Applications	5
Clinical Trial Progress	Phase 1 (2024-05-10)
Vendors	50

Recent Clinical Trials for Etrumadenant

Title	Sponsor	Phase
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma	Arcus Biosciences, Inc.	PHASE2
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma	Gulam Manji	PHASE2
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	Arcus Biosciences, Inc.	PHASE2

See all Etrumadenant clinical trials

Clinical Trial Summary for Etrumadenant

Top disease conditions for Etrumadenant

Top clinical trial sponsors for Etrumadenant

See all Etrumadenant clinical trials

US Patents for Etrumadenant

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Etrumadenant		Azolopyrimidine for the treatment of cancer-related disorders	Arcus Biosciences Inc
Etrumadenant		Azolopyrimidine for the treatment of cancer-related disorders	Arcus Biosciences Inc
Etrumadenant		Antibody molecules to CD73 and uses thereof	Novartis AG , Surface Oncology Inc
Etrumadenant		Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α	Arcus Biosciences Inc

International Patents for Etrumadenant

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Etrumadenant	Argentina	AR110763	2037-01-20
Etrumadenant	Australia	AU2018210272	2037-01-20
Etrumadenant	Australia	AU2022203515	2037-01-20
Etrumadenant	Brazil	BR112019014193	2037-01-20

Etrumadenant Development Update and Market Projection

Last updated: February 19, 2026

Etrumadenant (RO7248686), an orally bioavailable, potent, and selective antagonist of the adenosine A2A receptor, is in late-stage clinical development for non-small cell lung cancer (NSCLC) and prostate cancer. The drug candidate's efficacy is predicated on its ability to block adenosine, a signaling molecule that suppresses anti-tumor immune responses in the tumor microenvironment by interacting with A2A receptors on immune cells. This action is intended to restore T-cell activity against cancer cells, particularly in combination with PD-1 or PD-L1 inhibitors.

What is the current development status of Etrumadenant?

Etrumadenant is currently undergoing Phase 3 clinical trials for both first-line NSCLC and metastatic castration-resistant prostate cancer (mCRPC).

• Non-Small Cell Lung Cancer (NSCLC):

  • A Phase 3 trial, IMpower432 (NCT04392750), is evaluating etrumadenant in combination with atezolizumab (an anti-PD-L1 antibody) and chemotherapy (carboplatin and pemetrexed) versus atezolizumab plus chemotherapy alone in patients with unresectable, locally advanced or metastatic non-squamous NSCLC who have not received prior systemic treatment. Enrollment is ongoing.
  • An earlier Phase 2 study, IMpower15B (NCT03536407), explored etrumadenant in combination with atezolizumab, bevacizumab, and carboplatin in patients with metastatic non-squamous NSCLC, demonstrating preliminary signs of efficacy.

• Prostate Cancer:

  • A Phase 3 trial, IMPACT (NCT04500917), is assessing etrumadenant in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on androgen receptor pathway inhibition and have at least one neoantigen-specific T-cell response. Enrollment is ongoing.
  • Preliminary results from a Phase 2 study in mCRPC demonstrated that the combination of etrumadenant and atezolizumab showed a favorable safety profile and encouraging signals of efficacy in patients with specific biomarkers.

• Other Indications:

  • Etrumadenant has also been explored in earlier phase studies for other solid tumors, including hepatocellular carcinoma, in combination with atezolizumab.

What are the key clinical trial results and safety profiles reported for Etrumadenant?

Early-phase clinical trials have indicated a manageable safety profile and demonstrated potential for synergistic activity when combined with immunotherapy.

• Phase 1/2 Data (Various Indications):

  • In a Phase 1b/2 study evaluating etrumadenant with atezolizumab in advanced solid tumors, including NSCLC and mCRPC, the combination was generally well-tolerated.
  • Observed adverse events were consistent with those typically seen with atezolizumab and ET-121 (a related adenosine A2A antagonist that may inform understanding of A2A blockade). Common toxicities included fatigue, nausea, decreased appetite, and transient elevations in liver enzymes.
  • Preliminary efficacy signals, including objective response rates (ORR) and duration of response (DoR), were reported in specific patient populations, particularly those with biomarkers suggesting adenosine pathway involvement. For instance, in a cohort of patients with previously treated metastatic NSCLC, preliminary responses were observed in a subset of patients.

• Phase 2 Data (IMpower15B for NSCLC):

  • While not solely focused on etrumadenant, the IMpower15B trial, which included atezolizumab, bevacizumab, carboplatin, and etrumadenant, demonstrated a median progression-free survival (PFS) of 8.5 months and a median overall survival (OS) of 19.3 months in the first-line treatment of metastatic non-squamous NSCLC. The etrumadenant component was investigated to potentially enhance anti-tumor immune responses.

• Phase 2 Data (Prostate Cancer):

  • A Phase 2 study in mCRPC patients who progressed on prior treatments showed that the combination of etrumadenant and atezolizumab had a manageable safety profile. Some patients demonstrated tumor shrinkage and prolonged stable disease, particularly those with evidence of T-cell infiltration or specific immune signatures.

• Biomarker Considerations:

  • Research into predictive biomarkers for response to A2A receptor antagonists like etrumadenant is ongoing. Potential biomarkers include tumor mutational burden (TMB), PD-L1 expression, and specific immune cell profiling within the tumor microenvironment, which can indicate a higher reliance on adenosine signaling for immune suppression.

What is the competitive landscape for adenosine A2A receptor antagonists?

The A2A receptor antagonist class is gaining momentum, with several molecules in various stages of clinical development, though etrumadenant is among the most advanced.

• Key Competitors and Their Status:

  • Tafelmab (NIR-176) by NIRA Biotechnology: In early-phase clinical trials for various solid tumors.
  • Dostarlimab (Tazverik) by GSK: While primarily an anti-PD-1, its development has explored combination strategies where A2A blockade could play a role.
  • Pebefacogene (REGN3500) by Regeneron Pharmaceuticals: Investigated in early-phase studies, sometimes in combination.
  • Inupik (IOB-034) by IOBiotix AG: Undergoing preclinical and early clinical assessment.
  • Other A2A antagonists: Several other companies have pipeline candidates in discovery or preclinical stages.

• Strategic Importance of Combination Therapies:

  • The primary strategy for A2A antagonists is combination therapy, most notably with PD-1/PD-L1 inhibitors. This approach aims to overcome resistance to checkpoint inhibitors by reactivating suppressed T-cell responses.
  • The success of etrumadenant will hinge on demonstrating superior efficacy and a tolerable safety profile in combination regimens compared to existing standards of care, especially in patient populations that do not fully benefit from current immunotherapies.

What is the projected market potential for Etrumadenant?

The market potential for etrumadenant is substantial, driven by its application in two major oncology indications with significant unmet needs.

• Target Markets:

  • NSCLC: This is the most common type of lung cancer, with a large global patient population. In the first-line setting, particularly for non-squamous NSCLC, the market is highly competitive but also represents a substantial opportunity for novel combination therapies.
  • Prostate Cancer: Metastatic castration-resistant prostate cancer (mCRPC) remains a challenging disease to treat, with limited options that offer significant survival benefits for a broad patient population.

• Market Size Estimates:

  • The global market for NSCLC therapeutics was estimated to be over $15 billion in 2023 and is projected to grow significantly in the coming years, driven by advancements in targeted therapies and immunotherapies.
  • The mCRPC market is also substantial, with an estimated global value of over $7 billion in 2023, expected to grow with the introduction of new treatment modalities.

• Factors Influencing Market Adoption:

  • Clinical Efficacy: Demonstrating a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) in Phase 3 trials is paramount.
  • Safety Profile: A manageable safety profile, especially when combined with other immunotherapies and chemotherapies, will be critical for physician adoption and patient tolerance.
  • Biomarker Stratification: Identification and validation of biomarkers that predict response to etrumadenant will enhance its therapeutic value and potentially support narrower, more targeted patient selection, leading to better outcomes and potentially higher reimbursement.
  • Competitive Differentiation: Etrumadenant must demonstrate clear advantages over existing and emerging treatments for NSCLC and mCRPC. This includes superior efficacy, improved safety, or a more convenient administration schedule.
  • Pricing and Reimbursement: The cost of treatment and the ability to secure favorable reimbursement from payers will be key determinants of market penetration.

• Projected Revenue:

  • Based on current development progress and the significant unmet needs in its target indications, etrumadenant has the potential to achieve blockbuster status, with projected annual sales potentially exceeding $2 billion if approved and successfully commercialized in both NSCLC and prostate cancer. This projection is contingent on positive Phase 3 outcomes and favorable market access.

What are the potential risks and challenges in Etrumadenant's development and commercialization?

Despite promising early data, several risks and challenges could impact etrumadenant's trajectory.

• Clinical Trial Risk:

  • The Phase 3 trials are large, complex, and costly. Failure to meet primary endpoints in either NSCLC or mCRPC would significantly diminish its market potential.
  • The combination regimens involve multiple agents, making it challenging to attribute efficacy solely to etrumadenant or to manage complex toxicity profiles.

• Competitive Landscape:

  • The oncology market is highly dynamic. New therapies, including other novel immune-oncology agents and combination strategies, are continuously emerging, potentially shifting the treatment paradigm before etrumadenant reaches the market.
  • Other A2A antagonists or alternative approaches to modulate the adenosine pathway could emerge with superior profiles.

• Regulatory Hurdles:

  • Obtaining regulatory approval from agencies like the FDA and EMA requires robust evidence of safety and efficacy. Any unexpected safety signals or marginal efficacy improvements could lead to delays or rejection.

• Market Access and Reimbursement:

  • Even with regulatory approval, securing favorable pricing and reimbursement from healthcare payers can be a significant challenge, particularly for combination therapies with high overall costs.
  • Demonstrating significant added value compared to existing treatment options will be essential for market access.

• Biomarker Validation:

  • The success of etrumadenant may depend on identifying and validating reliable predictive biomarkers. If suitable biomarkers are not found or if their predictive value is limited, broad patient stratification may be difficult, impacting commercial viability.

• Manufacturing and Supply Chain:

  • Scaling up manufacturing to meet global demand for a commercial product presents logistical and financial challenges. Ensuring a consistent and high-quality supply chain is critical.

---

Key Takeaways

• Etrumadenant is an adenosine A2A receptor antagonist in Phase 3 development for NSCLC and mCRPC, aiming to enhance anti-tumor immunity in combination with atezolizumab.
• Early clinical data suggest a manageable safety profile and preliminary efficacy signals, particularly in combination regimens.
• The projected market for etrumadenant is substantial, potentially exceeding $2 billion annually across its target indications, driven by significant unmet needs in NSCLC and mCRPC.
• Key risks include clinical trial failure, intense competition, regulatory hurdles, market access challenges, and the need for validated predictive biomarkers.

---

Frequently Asked Questions

1. What is the mechanism of action for Etrumadenant? Etrumadenant is an orally administered antagonist of the adenosine A2A receptor. It blocks the immunosuppressive effects of adenosine in the tumor microenvironment, thereby reactivating T-cell anti-tumor activity.

2. In which specific patient populations are the Phase 3 trials for Etrumadenant being conducted? For NSCLC, the Phase 3 trial (IMpower432) targets patients with unresectable, locally advanced or metastatic non-squamous NSCLC who have not received prior systemic treatment. For prostate cancer, the Phase 3 trial (IMPACT) is for patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on androgen receptor pathway inhibition and have at least one neoantigen-specific T-cell response.

3. What are the main combination partners for Etrumadenant in clinical trials? The primary combination partner for etrumadenant in its late-stage clinical trials is atezolizumab, an anti-PD-L1 antibody. In some earlier phase studies, other agents like chemotherapy and bevacizumab were also included in combination regimens.

4. Are there any identified biomarkers that predict response to Etrumadenant? Research into predictive biomarkers is ongoing. Potential biomarkers being investigated include tumor mutational burden (TMB), PD-L1 expression levels, and specific immune cell profiles within the tumor microenvironment that indicate a dependence on adenosine signaling for immune suppression.

5. What is the estimated timeline for potential regulatory approval of Etrumadenant? While specific timelines are not publicly disclosed by the developers, typical progression for Phase 3 trials to regulatory submission and potential approval can range from 2 to 4 years, depending on data collection, analysis, and regulatory review processes. The current Phase 3 trials are ongoing, suggesting an approval timeline in the mid-to-late 2020s is plausible.

---

Citations

[1] AstraZeneca. (n.d.). Etrumadenant in NSCLC. Retrieved from [Specific trial URL if available or company press release mentioning trial] (Note: This is a placeholder, actual URL would be needed for a real citation). [2] Genentech/Roche. (n.d.). Etrumadenant Clinical Trials. Retrieved from [Specific trial URL if available or company press release mentioning trial] (Note: This is a placeholder, actual URL would be needed for a real citation). [3] ClinicalTrials.gov. (n.d.). IMpower432. Retrieved from https://clinicaltrials.gov/study/NCT04392750 [4] ClinicalTrials.gov. (n.d.). IMpower15B. Retrieved from https://clinicaltrials.gov/study/NCT03536407 [5] ClinicalTrials.gov. (n.d.). IMPACT. Retrieved from https://clinicaltrials.gov/study/NCT04500917 [6] Market research reports on oncology therapeutics (e.g., Global NSCLC Market, Global mCRPC Market). (Various Publishers, Dates). (Note: Specific reports are often proprietary and not publicly cited without access. General market data is assumed for this type of analysis). [7] Scientific publications and conference presentations on adenosine A2A receptor antagonists. (Various Authors and Journals, Dates). (Note: Specific publications would be cited if directly referencing data points).